Tarsus Pharmaceuticals (TARS) Total Non-Current Liabilities (2019 - 2026)

Tarsus Pharmaceuticals' Total Non-Current Liabilities history runs 8 years deep, the most recent figure standing at $216.1 million for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities changed N/A year-over-year to $216.1 million; the TTM figure through Mar 2026 stood at $216.1 million (changed N/A YoY), while the FY2025 annual figure was $208.1 million, up 36.52% from the prior year.
• Total Non-Current Liabilities was $216.1 million for Q1 2026 at Tarsus Pharmaceuticals, up from $208.1 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $216.1 million in Q1 2026 to a low of $31.0 million in Q2 2022.
• Historically, Total Non-Current Liabilities has averaged $95.2 million across 5 years, with a median of $66.8 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities surged 224.45% in 2022, then climbed 18.81% in 2023.
• A 5-year view of Total Non-Current Liabilities shows it stood at $34.9 million in 2022, then soared by 91.48% to $66.8 million in 2023, then soared by 128.38% to $152.5 million in 2024, then soared by 36.52% to $208.1 million in 2025, then increased by 3.83% to $216.1 million in 2026.
• The last three Total Non-Current Liabilities figures came in at $216.1 million (Q1 2026), $208.1 million (Q4 2025), and $189.3 million (Q3 2025), per Business Quant data.